Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells
2001
Vitamin D Analogue EB1089 is More Effective on Resistant Breast Cancer Cells
publication
Author Information
Author(s): Larsen S S, Heiberg I, Lykkesfeldt A E
Primary Institution: Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society
Hypothesis
Are anti-oestrogen resistant breast cancer cell lines more sensitive to the vitamin D analogue EB1089 than the parent MCF-7 cells?
Conclusion
The study found that anti-oestrogen resistant breast cancer cell lines are more sensitive to treatment with EB1089 compared to the parent MCF-7 cells.
Supporting Evidence
- The resistant cell lines express lower levels of the anti-apoptotic protein Bcl-2.
- Bcl-2 may be a predictive marker for response to EB1089 treatment.
Takeaway
Some breast cancer cells that don't respond to regular treatments might actually respond better to a vitamin D treatment called EB1089.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website